Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Sponsor: Mayo Clinic
Summary
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
Official title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04
Completion Date
2031-12
Last Updated
2025-08-22
Healthy Volunteers
No
Interventions
Metyrapone 250 mg Oral Tablets
Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg
Placebo
Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding